Corvus Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense
Corvus Pharmaceuticals, Inc. (CRVS) reported Share-based Payment Arrangement, Expense of $2.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.61M, a 107.72% increase year-over-year.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.65M, a 111.83% increase year-over-year.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.57M, a 93.60% increase year-over-year.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.25M, a 70.40% increase year-over-year.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2025 was $5.33M, a 77.49% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2024 was $3.00M, a 39.87% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2023 was $2.15M, a 20.25% decline from fiscal 2022.
- Corvus Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2022 was $2.69M, a 36.39% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.61M 10-Q · filed 2026-08-06 | $5.26M 10-Q · filed 2026-08-06 | $6.83M derived: sum of 3 quarters · filed 2026-08-06 | $8.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-07 | $4.22M derived: sum of 2 quarters · filed 2026-05-07 | $5.47M derived: sum of 3 quarters · filed 2026-05-07 | $6.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.82M derived: sum of 2 quarters · filed 2026-03-12 | $4.08M derived: sum of 3 quarters · filed 2026-08-06 | $5.33M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-04 | $2.50M derived: sum of 2 quarters · filed 2026-08-06 | $3.76M 10-Q · filed 2025-11-04 | $4.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.26M 10-Q · filed 2026-08-06 | $2.51M 10-Q · filed 2026-08-06 | $3.32M derived: sum of 3 quarters · filed 2026-08-06 | $4.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.25M 10-Q · filed 2026-05-07 | $2.06M derived: sum of 2 quarters · filed 2026-05-07 | $2.80M derived: sum of 3 quarters · filed 2026-05-07 | $3.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.55M derived: sum of 2 quarters · filed 2026-03-12 | $2.31M derived: sum of 3 quarters · filed 2026-03-12 | $3.00M 10-K · filed 2026-03-12 |
| 2024-09-30 | $733.00K 10-Q · filed 2025-11-04 | $1.50M derived: sum of 2 quarters · filed 2025-11-04 | $2.19M 10-Q · filed 2025-11-04 | $2.76M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $768.00K 10-Q · filed 2025-08-07 | $1.46M 10-Q · filed 2025-08-07 | $2.03M derived: sum of 3 quarters · filed 2026-03-12 | $2.58M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $689.00K 10-Q · filed 2025-05-08 | $1.26M derived: sum of 2 quarters · filed 2026-03-12 | $1.81M derived: sum of 3 quarters · filed 2026-03-12 | $2.34M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $572.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.12M derived: sum of 2 quarters · filed 2026-03-12 | $1.66M derived: sum of 3 quarters · filed 2026-03-12 | $2.15M 10-K · filed 2026-03-12 |
| 2023-09-30 | $546.00K 10-Q · filed 2024-11-12 | $1.08M derived: sum of 2 quarters · filed 2024-11-12 | $1.57M 10-Q · filed 2024-11-12 | $2.19M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | $537.00K 10-Q · filed 2024-08-06 | $1.03M 10-Q · filed 2024-08-06 | $1.65M derived: sum of 3 quarters · filed 2025-03-25 | $2.31M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | $492.00K 10-Q · filed 2024-05-07 | $1.11M derived: sum of 2 quarters · filed 2025-03-25 | $1.77M derived: sum of 3 quarters · filed 2025-03-25 | $2.44M derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $1.28M derived: sum of 2 quarters · filed 2025-03-25 | $1.95M derived: sum of 3 quarters · filed 2025-03-25 | $2.69M 10-K · filed 2025-03-25 |
| 2022-09-30 | $658.00K 10-Q · filed 2023-11-07 | $1.33M derived: sum of 2 quarters · filed 2023-11-07 | $2.07M 10-Q · filed 2023-11-07 | $2.81M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $675.00K 10-Q · filed 2023-08-08 | $1.41M 10-Q · filed 2023-08-08 | $2.15M derived: sum of 3 quarters · filed 2024-03-19 | $3.25M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $739.00K 10-Q · filed 2023-05-08 | $1.48M derived: sum of 2 quarters · filed 2024-03-19 | $2.57M derived: sum of 3 quarters · filed 2024-03-19 | $3.75M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.83M derived: sum of 2 quarters · filed 2024-03-19 | $3.01M derived: sum of 3 quarters · filed 2024-03-19 | $4.23M 10-K · filed 2024-03-19 |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-03 | $2.27M derived: sum of 2 quarters · filed 2022-11-03 | $3.49M 10-Q · filed 2022-11-03 | $4.73M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $1.17M 10-Q · filed 2022-08-08 | $2.40M 10-Q · filed 2022-08-08 | $3.63M derived: sum of 3 quarters · filed 2023-03-28 | $4.92M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $1.23M 10-Q · filed 2022-05-05 | $2.46M derived: sum of 2 quarters · filed 2023-03-28 | $3.74M derived: sum of 3 quarters · filed 2023-03-28 | $5.13M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $2.52M derived: sum of 2 quarters · filed 2023-03-28 | $3.90M derived: sum of 3 quarters · filed 2023-03-28 | $5.75M 10-K · filed 2023-03-28 |
| 2020-09-30 | $1.28M 10-Q · filed 2021-11-01 | $2.67M derived: sum of 2 quarters · filed 2021-11-01 | $4.51M 10-Q · filed 2021-11-01 | $6.26M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $1.38M 10-Q · filed 2021-08-02 | $3.23M 10-Q · filed 2021-08-02 | $4.98M derived: sum of 3 quarters · filed 2022-03-10 | $6.72M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $1.84M 10-Q · filed 2021-04-29 | $3.59M derived: sum of 2 quarters · filed 2022-03-10 | $5.34M derived: sum of 3 quarters · filed 2022-03-10 | $7.24M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.50M derived: sum of 2 quarters · filed 2022-03-10 | $5.39M derived: sum of 3 quarters · filed 2022-03-10 | $7.35M 10-K · filed 2022-03-10 |
| 2019-09-30 | $1.75M 10-Q · filed 2020-10-29 | $3.65M derived: sum of 2 quarters · filed 2020-10-29 | $5.60M 10-Q · filed 2020-10-29 | $7.41M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $1.90M 10-Q · filed 2020-07-30 | $3.85M 10-Q · filed 2020-07-30 | $5.66M derived: sum of 3 quarters · filed 2021-03-25 | $7.45M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $1.95M 10-Q · filed 2020-04-30 | $3.76M derived: sum of 2 quarters · filed 2021-03-25 | $5.55M derived: sum of 3 quarters · filed 2021-03-25 | $7.29M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $3.60M derived: sum of 2 quarters · filed 2021-03-25 | $5.33M derived: sum of 3 quarters · filed 2021-03-25 | $7.13M 10-K · filed 2021-03-25 |
| 2018-09-30 | $1.79M 10-Q · filed 2019-10-29 | $3.53M derived: sum of 2 quarters · filed 2019-10-29 | $5.33M 10-Q · filed 2019-10-29 | $7.07M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | $1.74M 10-Q · filed 2019-08-01 | $3.54M 10-Q · filed 2019-08-01 | $5.28M derived: sum of 3 quarters · filed 2020-03-09 | $6.78M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | $1.80M 10-Q · filed 2019-05-09 | $3.54M derived: sum of 2 quarters · filed 2020-03-09 | $5.04M derived: sum of 3 quarters · filed 2020-03-09 | $6.56M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $3.24M derived: sum of 2 quarters · filed 2020-03-09 | $4.76M derived: sum of 3 quarters · filed 2020-03-09 | $6.23M 10-K · filed 2020-03-09 |
| 2017-09-30 | $1.50M 10-Q · filed 2018-11-01 | $3.02M derived: sum of 2 quarters · filed 2018-11-01 | $4.49M 10-Q · filed 2018-11-01 | $5.54M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $1.52M 10-Q · filed 2018-08-02 | $2.99M 10-Q · filed 2018-08-02 | $4.04M derived: sum of 3 quarters · filed 2019-03-07 | $5.30M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $1.47M 10-Q · filed 2018-05-03 | $2.52M derived: sum of 2 quarters · filed 2019-03-07 | $3.78M derived: sum of 3 quarters · filed 2019-03-07 | $4.85M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $2.31M derived: sum of 2 quarters · filed 2019-03-07 | $3.39M derived: sum of 3 quarters · filed 2019-03-07 | $3.83M 10-K · filed 2019-03-07 |
| 2016-09-30 | $1.26M 10-Q · filed 2017-11-02 | $2.34M derived: sum of 2 quarters · filed 2017-11-02 | $2.78M 10-Q · filed 2017-11-02 | $3.07M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $1.07M 10-Q · filed 2017-08-03 | $1.52M 10-Q · filed 2017-08-03 | $1.80M derived: sum of 3 quarters · filed 2018-03-01 | $1.93M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $441.00K 10-Q · filed 2017-05-04 | $727.00K derived: sum of 2 quarters · filed 2018-03-01 | $850.00K derived: sum of 3 quarters · filed 2018-03-01 | $867.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $409.00K derived: sum of 2 quarters · filed 2018-03-01 | $426.00K derived: sum of 3 quarters · filed 2018-03-01 | $428.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $123.00K 10-Q · filed 2016-11-03 | $140.00K derived: sum of 2 quarters · filed 2016-11-03 | $142.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $17.00K 10-Q · filed 2016-08-04 | $20.00K 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $2.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |